Invion
  • Invion
    • Board of Directors
    • Management Team
    • Corporate Governance
  • The Photosoft™ technology
  • Market Announcements
  • Contact
  • ASX:IVX
Home › ASX Releases › Appendix 4C

Appendix 4C

Posted on January 28, 2016 by Company Secretary
‹ Appendix 3B and Cleansing Notice
Changes to Board Structure ›
Posted in ASX Releases
Latest Releases
  • Invion selects Guilin Xingda to manufacture light-therapy medical equipment
  • Invion appoints cancer experts to Scientific Advisory Board
  • Invion Collaborates to Develop Powerful Skin Cancer Gel
  • Invion spin-off Chronic Airway Therapeutics selects leading CRO for the future development of nadolol
  • New formulation of Photosoft therapy shows increased effect in ovarian cancer
News & Media Archive
  • January 2019
  • November 2018
  • September 2018
  • August 2018
  • July 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • August 2017
  • July 2017
  • April 2017
  • February 2017
  • January 2017
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • August 2014
  • July 2014
  • June 2014
  • April 2014
  • March 2014
  • February 2014
  • January 2014
  • December 2013
  • November 2013
  • October 2013
  • September 2013
  • August 2013
  • July 2013
  • June 2013
  • May 2013
  • April 2013
  • March 2013
  • February 2013
  • January 2013
  • December 2012
  • November 2012
  • October 2012
  • September 2012
  • August 2012
  • July 2012
News & Media
  • Analyst Coverage
  • Annual Review
  • ASX Releases
  • Financial Reports
  • Presentations
© 2019 Invion Limited
↑